Vanda Pharmaceuticals (VNDA) Issues Earnings Results, Beats Estimates By $0.08 EPS

Vanda Pharmaceuticals (NASDAQ:VNDA) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.08, Bloomberg Earnings reports. The company had revenue of $44.28 million for the quarter, compared to the consensus estimate of $44.00 million. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The firm’s revenue for the quarter was up 15.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.08 earnings per share.

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) opened at $15.85 on Thursday. Vanda Pharmaceuticals has a twelve month low of $11.90 and a twelve month high of $18.99. The company has a market cap of $712.10, a P/E ratio of -49.53 and a beta of 1.23.

A number of brokerages recently weighed in on VNDA. Jefferies Group restated a “buy” rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research report on Wednesday, October 18th. ValuEngine downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 26th. Oppenheimer restated a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday, January 8th. Finally, Piper Jaffray Companies set a $26.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, October 19th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $21.14.

In other Vanda Pharmaceuticals news, CFO James Patrick Kelly sold 9,155 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $15.35, for a total transaction of $140,529.25. Following the completion of the sale, the chief financial officer now directly owns 144,721 shares of the company’s stock, valued at $2,221,467.35. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Gunther Birznieks sold 8,568 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $15.26, for a total transaction of $130,747.68. Following the sale, the senior vice president now directly owns 118,366 shares of the company’s stock, valued at $1,806,265.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 209,483 shares of company stock valued at $3,205,205. 7.60% of the stock is owned by corporate insiders.

WARNING: This piece of content was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/14/vanda-pharmaceuticals-vnda-announces-quarterly-earnings-results.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply